According to IMARC Group’s latest research report, titled “PEGylated Proteins Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032,” offers a comprehensive analysis of the industry, which comprises insights on the PEGylated proteins market trends. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The global PEGylated proteins market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.8 Billion by 2032, exhibiting a growth rate (CAGR) of 8.87% during 2024-2032.
PEGylated Proteins Market Overview:
Pegylated proteins are a category of proteins that have undergone the process of pegylation, where polyethylene glycol (PEG) chains are attached to them. This modification enhances the proteins’ therapeutic potential by improving their solubility, stability, and half-life in the human body. The process of pegylation masks the protein from the host’s immune system, reducing immunogenicity and extending the time it circulates in the bloodstream. As a result, pegylated proteins are increasingly used in medical treatments, offering prolonged action compared to their non-pegylated counterparts. They work by maintaining therapeutic levels of drugs in the bloodstream for extended periods, which can lead to more effective disease management with fewer doses.
Get Sample Copy of Report at – https://www.imarcgroup.com/pegylated-proteins-market/requestsample
PEGylated Proteins Market Trends:
The global market is primarily driven by the increasing prevalence of chronic diseases that require long-lasting therapeutic interventions. In line with this, the continuous advancements in drug delivery technologies, including pegylation, are also providing an impetus to the market. Moreover, the persistent efforts in research and development within the pharmaceutical industry are acting as a significant growth-inducing factor, leading to the discovery of novel applications for these proteins. In addition to this, the approval of pegylated protein-based therapies by regulatory bodies is resulting in a broader acceptance and use in clinical settings. Besides this, the aging population across the globe, more prone to chronic conditions, is creating lucrative opportunities for the market. The market is further driven by the expansion of healthcare infrastructure in emerging economies, coupled with increasing patient and healthcare provider awareness about the benefits of pegylated protein therapies.
Competitive Landscape with Key Players:
- Abcam plc
- Biomatrik Inc.
- Creative PEGWorks
- Iris Biotech GmbH
- JenKem Technology USA Inc.
- Laysan Bio Inc.
- NOF America Corporation (NOF Corporation)
- Profacgen
- Thermo Fisher Scientific Inc.
Key Market Segmentation:
Product Insights:
- Consumables
- PEGylation Reagents
- PEGylation Kits
- Services
Protein Type Insights:
- Colony Stimulating Factors
- Interferons
- Erythropoietin
- mAbs
- Recombinant Factor VII
- Others
Application Insights:
- Cancer Treatment
- Hepatitis
- Chronic Kidney Diseases
- Hemophilia
- Multiple Sclerosis
- Gastrointestinal Disorders
- Others
End User Insights:
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic and Research Institutes
Breakup by Region:
- North America (United States, Canada)
- Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key Highlights of the Report:
- Market Performance
- Market Outlook
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163